New NGS-Assay for HRD determination
Detection of mutations in 20 HRR genes and determination of the HRD status
The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
In both NGS assays, in addition to the BRCA1/2 mutational status, genomic instability is determined based on 24,000 SNPs, which are evenly distributed throughout the genome. The AmoyDx® HRD Complete Panel can be further used to detect SNVs, InDels and homozygous deletions in 20 genes involved in homologous recombination repair (HRR).
Please find a detailed description of the AmoyDx® HRD Complete Panel here.
This product is for research use only (RUO)
Further topics
PRAME (EPR20330) in dermatopathology
PRAME (PReferentially-expressed Antigen in MElanoma) was first described in a paper by Ikeda et al., through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. [1, 2]
Qualitative detection of NTRK3 and NTRK1 break apart
Recently, a second ZytoDot ® 2C probe for detecting rearrangements of the NTRK genes has become available: the new ZytoDot ® 2C SPEC NTRK3 Break Apart Probe (C-3079-100). Together with the already existing ZytoDot ® 2C SPEC NTRK1 Break Apart Probe (C-3078-100), a large range of NTRK rearrangements can be covered now. Both probes are designed for the qualitative detection of NTRK3 and NTRK1 rearrangements in FFPE tissue using the ZytoDot ® 2C CISH implementation Kit.
